TAK 195

Drug Profile

TAK 195

Alternative Names: Sabin-inactivated poliovirus vaccine - Takeda; Sabin-IPV - Takeda; sIPV - Takeda

Latest Information Update: 23 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Poliomyelitis

Most Recent Events

  • 07 Jun 2017 Phase-I/II clinical trials in Poliomyelitis (Prevention, In children, In infants, In adolescents, In adults) in Panama (IM) (NCT03092791)
  • 03 Apr 2017 Takeda plans a phase I/II trial for Poliomyelitis (Prevention, In infants, In children, In adolescents, In adults) (NCT03092791)
  • 08 May 2016 Early research in Poliomyelitis (Prevention) in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top